These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25769296)

  • 21. New drugs for rheumatoid arthritis.
    Kalil AC
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15609422
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 23. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of biologic agents in rheumatoid arthritis: introduction.
    Silman AJ
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
    [No Abstract]   [Full Text] [Related]  

  • 25. The updated guidelines on the use of rituximab in rheumatoid arthritis.
    Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
    Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
    [No Abstract]   [Full Text] [Related]  

  • 26. Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?
    Caporali R; Codullo V; Cipriani P; Giacomelli R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii1-vii4. PubMed ID: 30289536
    [No Abstract]   [Full Text] [Related]  

  • 27. Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis.
    Smolen JS; Aletaha D
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):296-7. PubMed ID: 18461061
    [No Abstract]   [Full Text] [Related]  

  • 28. Escalated conventional therapy for rheumatoid arthritis patients.
    Smith MD
    Rheumatology (Oxford); 2004 Sep; 43(9):1199; author reply 1199-1200. PubMed ID: 15317963
    [No Abstract]   [Full Text] [Related]  

  • 29. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 30. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 32. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 33. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.
    Tanaka Y; Martin Mola E
    Ann Rheum Dis; 2014 Sep; 73(9):1595-7. PubMed ID: 24833786
    [No Abstract]   [Full Text] [Related]  

  • 34. Radiographic progression in rheumatoid arthritis: does it still happen and does it matter?
    Bykerk VP
    J Rheumatol; 2014 Dec; 41(12):2337-9. PubMed ID: 25452176
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of rheumatoid arthritis.
    Emery P
    BMJ; 2006 Jan; 332(7534):152-5. PubMed ID: 16424492
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

  • 39. Rheumatoid arthritis: still a chronic disease.
    Miossec P
    Lancet; 2013 Mar; 381(9870):884-6. PubMed ID: 23332235
    [No Abstract]   [Full Text] [Related]  

  • 40. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.